Alliancebernstein L.P. Supernus Pharmaceuticals, Inc. Transaction History

Alliancebernstein L.P.

$280 Billion
Q4 2024

A detailed history of Alliancebernstein L.P. transactions in Supernus Pharmaceuticals, Inc. stock. As of the latest transaction made, Alliancebernstein L.P. holds 54,162 shares of SUPN stock, worth $2.12 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

54,162

Previous 54,010 0.28%

Holding current value

$2.12 Million

Previous $1.68 Million 16.27%

% of portfolio

0.0%

Previous 0.0%

25 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 12, 2025	BUY	$31.89 - $37.83 $4,847 - $5,750	152 Added 0.28%	54,162 $1.96 Million
Q3 2024 Nov 14, 2024	SELL	$25.77 - $35.16 $79,887 - $108,995	-3,100 Reduced 5.43%	54,010 $1.68 Million
Q1 2024 May 14, 2024	SELL	$27.11 - $35.17 $75,636 - $98,124	-2,790 Reduced 4.66%	57,110 $1.95 Million
Q4 2023 Feb 14, 2024	SELL	$22.72 - $29.68 $66,296 - $86,606	-2,918 Reduced 4.65%	59,900 $1.73 Million
Q2 2023 Aug 15, 2023	SELL	$29.91 - $38.73 $239 - $309	-8 Reduced 0.01%	62,818 $1.89 Million
Q1 2023 May 15, 2023	SELL	$34.93 - $42.03 $278,392 - $334,979	-7,970 Reduced 11.26%	62,826 $2.28 Million
Q4 2022 Feb 14, 2023	SELL	$31.09 - $37.88 $76,792 - $93,563	-2,470 Reduced 3.37%	70,796 $2.53 Million
Q3 2022 Nov 15, 2022	BUY	$28.79 - $35.41 $119,795 - $147,341	4,161 Added 6.02%	73,266 $2.48 Million
Q2 2022 Aug 15, 2022	SELL	$25.33 - $34.25 $96,102 - $129,944	-3,794 Reduced 5.2%	69,105 $2 Million
Q1 2022 May 13, 2022	BUY	$28.51 - $32.9 $5,017 - $5,790	176 Added 0.24%	72,899 $2.36 Million
Q4 2021 Feb 14, 2022	BUY	$26.37 - $34.22 $2,452 - $3,182	93 Added 0.13%	72,723 $2.12 Million
Q3 2021 Nov 10, 2021	SELL	$23.54 - $31.39 $161,249 - $215,021	-6,850 Reduced 8.62%	72,630 $1.94 Million
Q2 2021 Jul 30, 2021	BUY	$26.72 - $33.19 $144,929 - $180,022	5,424 Added 7.32%	79,480 $2.45 Million
Q1 2021 May 06, 2021	SELL	$24.15 - $31.45 $576,702 - $751,026	-23,880 Reduced 24.38%	74,056 $1.94 Million
Q4 2020 Feb 08, 2021	BUY	$17.7 - $25.81 $442,429 - $645,146	24,996 Added 34.27%	97,936 $2.46 Million
Q3 2020 Nov 12, 2020	SELL	$20.2 - $25.05 $28,482 - $35,320	-1,410 Reduced 1.9%	72,940 $1.52 Million
Q2 2020 Aug 13, 2020	BUY	$17.09 - $24.89 $36,914 - $53,762	2,160 Added 2.99%	74,350 $1.77 Million
Q1 2020 May 14, 2020	BUY	$14.45 - $24.69 $1,445 - $2,469	100 Added 0.14%	72,190 $1.3 Million
Q4 2019 Feb 18, 2020	SELL	$19.93 - $29.13 $1.29 Million - $1.89 Million	-64,870 Reduced 47.36%	72,090 $1.71 Million
Q3 2019 Nov 14, 2019	SELL	$25.47 - $33.37 $303,093 - $397,102	-11,900 Reduced 7.99%	136,960 $3.76 Million
Q2 2019 Aug 14, 2019	BUY	$29.96 - $38.87 $638,148 - $827,931	21,300 Added 16.7%	148,860 $4.93 Million
Q4 2018 Feb 13, 2019	SELL	$30.84 - $49.51 $12,336 - $19,804	-400 Reduced 0.31%	127,560 $4.24 Million
Q2 2018 Aug 13, 2018	BUY	$44.1 - $59.85 $904,932 - $1.23 Million	20,520 Added 19.1%	127,960 $7.66 Million
Q1 2018 May 14, 2018	SELL	$37.15 - $46.9 $214,355 - $270,613	-5,770 Reduced 5.1%	107,440 $4.92 Million
Q3 2017 Nov 13, 2017	BUY	$36.75 - $49.65 $4.16 Million - $5.62 Million	113,210	113,210 $4.53 Million

Others Institutions Holding SUPN

# of Institutions

302

Shares Held

60.6M

Call Options Held

25.2K

Put Options Held

2.6K

View Full List

About SUPERNUS PHARMACEUTICALS, INC.

Ticker SUPN
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 53,495,300
Market Cap $2.09B
Description
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...

More about SUPN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Alliancebernstein L.P., based on Form 13F filings with the SEC.

News

Stay updated on Alliancebernstein L.P. with notifications on news.

Account

Alliancebernstein L.P. Supernus Pharmaceuticals, Inc. Transaction History